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DOI 10.1016/j.ccr.2011.11.016SUMMARYThe ATM kinase and p53 are key tumor suppressor factors that control the genotoxic stress response
pathway. The ATM substrateMdm2 controls p53 activity by either targeting p53 for degradation or promoting
its synthesis by binding the p53mRNA. The physiological role and regulation of Mdm2’s dual function toward
p53 is not known. Here we show that ATM-dependent phosphorylation of Mdm2 at Ser395 is required for the
p53 mRNA-Mdm2 interaction. This event also promotes SUMO-conjugation of Mdm2 and its nucleoli accu-
mulation. Interferingwith the p53mRNA-Mdm2 interaction prevents p53 stabilization and activation following
DNA damage. These results demonstrate how ATM activity switches Mdm2 from a negative to a positive
regulator of p53 via the p53 mRNA.INTRODUCTION polyubiquitination and degradation by the 26S proteasomaATM is a key regulator of genome stability and initiator of cellular
signaling pathways required for the DNA damage response.
Mutations in ATM cause ataxia telangiectasia and result in the
development of cancers. Activation of ATM following double-
stranded DNA break involves its autophosphorylation and
monomerization and leads to phosphorylation of DNA damage
checkpoint proteins, such as p53, Chk2, c-Abl, BRCA-1, and
Mdm2 (Bartek et al., 2007; Kitagawa and Kastan, 2005; Shiloh,
2003). Different studies on ATM and the Wip1 phosphatase
have shown that phosphorylation and dephosphorylation of
p53 on Ser15 and Mdm2 on Ser395 are important for regulating
p53 activity (Banin et al., 1998; Canman et al., 1998; Khanna
et al., 1998; Lu et al., 2007; Maya et al., 2001).
Activation of p53 in response to stress leads to an early induc-
tion of Mdm2. Binding of Mdm2 to the N terminus of p53 pro-
motes either p53 monoubiquitination and nuclear export or p53Significance
The presented results show the importance of thep53mRNA-M
describe an additional function for anmRNA. The p53mRNA bi
ubiquitination of p53 while it stimulates p53 synthesis and pr
explain the previous paradox of why Mdm2 is upregulated b
pathway is active, Mdm2 serves as a positive regulator of p53w
is turned off. These results implicate a route for therapeutic inl
pathway (Honda et al., 1997; Li et al., 2003). Mdm2 also has
the capacity to regulate p53 mRNA translation indirectly via its
interaction with L26 or directly by binding to the p53mRNA (Can-
deias et al., 2008; Naski et al., 2009; Ofir-Rosenfeld et al., 2008).
Direct interaction with the mRNA also accounts for Mdm2’s
induction of XIAP synthesis (Gu et al., 2009). The p53 mRNA-
Mdm2 interaction is mediated by the C-terminal RING domain
of Mdm2 and the p53 mRNA sequence that encodes the
Mdm2 binding site in the N terminus of p53. This interaction
also controls Mdm2’s E3 ligase activity (Candeias et al., 2008).
Mdm2-dependent regulation of p53 expression and activity is
controlled via interactions with a number of different proteins
that are linked to the nucleolus. Several ribosomal factors,
such as L5, L11, and L23, have been shown to interact with
the central region of Mdm2 that contains its acid and zinc
domains (Deisenroth and Zhang, 2010). The central region of
Mdm2 also binds p14Arf, which can retain Mdm2 in the nucleolusdm2 interaction in activating p53 followingDNAdamage and
nding changesMdm2 activity and prevents Mdm2-mediated
omotes Mdm2 nucleolar localization. These results help to
y p53 in response to genotoxic stress. As long as the ATM
hile it rapidly degrades p53when the DNA damage response
tervention aimed at controlling Mdm2 activity toward p53.
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Mdm2 Activates p53 following Genotoxic Stressand prevent its export to the cytoplasm (Tao and Levine, 1999;
Weber et al., 1999). The localization of Mdm2 to nucleoli plays
a key role in p53 activation and involves the interaction of
Mdm2 with the PML (promyelocytic leukemia) tumor suppressor
protein (Bernardi et al., 2004; Boulon et al., 2010; Lohrum et al.,
2000; Weber et al., 1999). SUMOylation of PML, or of its interact-
ing partners, helps to target a number of different proteins to
PML nuclear bodies that are linked to a variety of different stress
and damage pathways that control transcription and translation
regulation, tumor suppression, DNA repair, and apoptosis (Ber-
nardi and Pandolfi, 2007; Heun, 2007; Lallemand-Breitenbach
and de The´, 2010).
Here we investigated the physiological role of the p53mRNA-
Mdm2 interaction in the well-described p53 tumor suppressor
pathway triggered by genotoxic stress.
RESULTS
Mdm2 Is Required to Promote p53 Activity following
DNA Damage in an ATM-Dependent Manner
Introduction of siRNA against Mdm2 in the human sarcoma cells
MLS1765 that express endogenous wild-type p53 (p53wt)
resulted in an increase in the number of cells undergoing apo-
ptosis, in line with the notion that Mdm2 is a negative regulator
of p53 activity under normal conditions. When MLS1765 cells
were exposed to the DNA-damaging agent doxorubicin, the
siRNA treatment against Mdm2 instead lead to a decrease in
the apoptotic numbers, indicating that Mdm2 helps to activate
apoptosis under conditions of genotoxic stress. siRNA against
ATM also reduced the amount of cells undergoing apoptosis
after doxorubicin treatment, and the strongest inhibition of
apoptosis was observed when siRNA for both Mdm2 and ATM
was introduced (Figure 1A; Figures S1A–S1C available online).
Introduction of exogenous Mdm2 and p53 in the p53/;
Mdm2/ double-KO (DKO) MEFs resulted in a four times
higher rate of p53-dependent apoptosis following induction of
DNA double-strand breaks by treating cells with etoposide
(Figure 1B).
To further investigate the role of Mdm2 as an activator of the
DNA damage-response pathway, we used the p53 null H1299
cell line, in which we introduced p53wt. Altering the levels of
Mdm2 by either knocking down endogenousMdm2 using siRNA
or by overexpressing Mdm2 revealed an Mdm2-dependent
inhibition of p53-induced apoptosis under normal conditions
and anMdm2-dependent augmented p53-dependent apoptosis
in response to genotoxic stress. This proapoptotic effect of
Mdm2 was significantly suppressed when the activity of endog-
enous ATM was diminished by siRNA or by overexpressing
the Wip1 phosphatase (Figure 1C). The latter reverses ATM-
mediated autophosphorylation and phosphorylation of p53 and
Mdm2 (Lu et al., 2007, 2005; Shreeram et al., 2006; Yoda
et al., 2008). Treatment of cells with an ATM kinase inhibitor
(ATMi) prevented Mdm2 from inducing apoptosis upon doxoru-
bicin treatment (Figure 1D; Figure S1D). Furthermore, we ob-
served that ectopically expressed Mdm2 acted as a negative
regulator of apoptosis in doxorubicin-treated cells expressing
endogenous p53 and Mdm2 but deficient for ATM (AT5-BIVA
cells) but acted as a positive regulator of apoptosis when exog-
enous ATM was introduced (Figure 1E). Taken together, these26 Cancer Cell 21, 25–35, January 17, 2012 ª2012 Elsevier Inc.results indicate that Mdm2 acts as a positive regulator of p53
activity following genotoxic stress in an ATM-dependent fashion.
Phosphorylation of Mdm2 at Ser395 Induces p53
Activity Independently of the p53-Mdm2Protein-Protein
Interaction
ATM mediates phosphorylation, directly or indirectly, through
Chk2 on several residues in the p53 N terminus (Shiloh, 2003),
which harbors the trans-activating domains and the Mdm2-
binding site (Oliner et al., 1993; Zhu et al., 1998). The current
model on how phosphorylation at these sites suppresses
Mdm2-dependent inhibition of p53 activity suggest that these
events prevent the p53-Mdm2 protein-protein interaction
(Cheng et al., 2009; Jimenez et al., 1999; Lu et al., 2007; Shieh
et al., 1997). This cannot, however, explain our observations
that Mdm2 not only stops being an inhibitor of p53 but in
fact enhances its activity following genotoxic stress. Hence,
other molecular mechanisms must be in place to explain
Mdm2’s switch from a negative to a positive regulator of p53.
To test this hypothesis, we first used the p76 Mdm2 isoform
(Mdm2p76), which lacks the N terminus and the capacity to
bind the p53 protein (Perry, 2004). Expression of Mdm2p76
stimulated p53-dependent apoptosis following DNA damage in
a similar way as the Mdm2wt, demonstrating that inhibition of
the p53-Mdm2 protein-protein interaction is not required in order
for Mdm2 to enhance p53 activity in response to DNA lesions
(Figure 2A; Figure S2A).
Mdm2 is phosphorylated at Ser395 by ATM (Maya et al., 2001)
and has been implicated in ATM-dependent activation of p53, so
we tested whether the proapoptotic disposition of Mdm2 is
dependent on the phosphorylation of Mdm2 at this residue.
The introduction of the S395Amutation inMdm2 caused a signif-
icant reduction in apoptosis in AT5-BIVA, H1299, and DKO cells
expressing ATM and p53 in the presence of doxorubicin, con-
firming the importance of this site for p53 activation in response
to DNA damage (Figure 2B). In each cell line, we observed
a decrease in p53 expression in cells exposed to doxorubicin
in the presence of Mdm2Ser395A, as compared to Mdm2wt
(Figure S2B). As can be expected, the relative levels of apoptosis
and p53 expression varies between cell lines depending on
sensitivity to the drug and the levels of p53 expression. The
binding of the p53mRNA to Mdm2 can stimulate p53 synthesis,
and, because Ser395 is situated close to the RING domain,
where the ability to bind p53 mRNA lies, we next assessed
whether the p53 mRNA-Mdm2 interaction plays a role in
Mdm2-mediated activation of p53 following DNA damage. We
expressed p53wt protein from an mRNA that carries a single
silent point mutation (p53L22L) and has a low affinity for Mdm2
(Candeias et al., 2008), or we expressed an Mdm2 protein that
carries a point mutation that reduces its affinity to RNA
(Mdm2G446S) (Elenbaas et al., 1996). Both mutants failed to
induce p53-dependent apoptosis in H1299 cells treated with
doxorubicin and, in fact, p53wt protein expressed from the
p53L22L mRNA was unable to induce a significant amount of
apoptosis in the presence of Mdm2wt (Figure 2C). On the con-
trary, introduction of the phospho-mimetic Mdm2S395D mutant
caused an increase in apoptosis as compared to Mdm2wt. In
addition, similar to what was observed in AT5-BIVA and DKO
cells, the level of p53 was low in H1299 cells in which the p53
Figure 1. Mdm2 Is a Positive Regulator of p53 Activity in Response to DNA Damage in an ATM-Dependent Manner
Flow cytometry analyses show the levels of apoptosis in different cell lines treated, or not, with the genotoxic drugs doxorubicin (doxo) (0.1–1 mM for 6–16 hr as
indicated below) or etoposide (5 mM for 20 hr).
(A) Suppression of Mdm2 and/or ATM using siRNA in MLS-1765 cells expressing endogenous wild-type p53 (p53wt) after treatment with 1 mMdoxo for 8 hr. The
data are normalized to the level of apoptosis in DMSO-treated cells with control siRNA (100%).
(B) Etoposide-induced apoptosis in Mdm2/;p53/ MEF cells expressing exogenous p53wt with, or without, exogenous Mdm2wt.
(C) The graph shows p53-induced apoptosis in p53/ H1299 cells expressing exogenous p53wt. The levels of Mdm2 were altered using siRNA to knock down
endogenousMdm2 levels, or by overexpressing (+) Mdm2. p53-dependent apoptosis in DMSO- compared to doxo-treated cells (0.1 mM for 16 hr) is shown. Light
bars (lanes 2, 5, and 8) represent low Mdm2 levels in cells treated with Mdm2 siRNA, light gray bars (lanes 3, 6, and 9) represent endogenous Mdm2 levels, and
darker gray bars (lanes 4, 7, and 10) are cells overexpressing Mdm2.
(D) The relative levels of p53-dependent apoptosis in the presence of exogenous Mdm2 in H1299 cells treated with doxo (0.1 mM for 16 hr) and ATM inhibitor
(ATMi, 10 mM for 20 hr).
(E) The levels of apoptosis in ATM/ cells (AT5-BIVA) expressing exogenousMdm2 and/or ATM in the presence of doxo (0.1 mM for 6 hr). The data are normalized
to the level of apoptosis in cells expressing endogenous Mdm2 (100%). Data are means ± s.d. of at least three independent experiments (*p < 0.05, **p < 0.01,
***p < 0.001). P values are as comparedwith doxo and no siRNA (A), noMdm2 (B and E), and as indicated (C). The data using H1299 cells (C and D) are normalized
to the levels of apoptosis in mock-transfected cells (0%).
See also Figure S1.
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Mdm2 Activates p53 following Genotoxic StressmRNA-Mdm2 interaction was interrupted (Figure S2C). These
results indicate that Mdm2’s positive effect on p53 activity
during genotoxic stress requires ATM-dependent phosphoryla-
tion of Mdm2 on Ser395 and the p53 mRNA-Mdm2 interaction.
Phosphorylation of Mdm2 at Ser395 by ATM Promotes
Its Interaction with the p53 mRNA
We next tested whether ATM activity affects the p53 mRNA-
Mdm2 interaction. The binding of p53 mRNA to Mdm2 was
analyzed by immunoprecipitation (IP) of Mdm2 followed by
quantitative RT-PCR (qRNA-coIP) (Candeias et al., 2008). An
approximately three-fold induction in the amount of p53 mRNA
bound to Mdm2 was observed following treatment of cells with
doxorubicin. This was prevented by the Mdm2S395A mutation
or by treating the cells with ATMi or with the general PI3K inhib-
itor wortmannin. The p53 mRNA-Mdm2 interaction was stabi-lized approximately five-fold by introducing the Mdm2S395D
mutation in the absence of doxorubicin. Treatment with doxoru-
bicin had no significant additional effect on the p53 mRNA-
Mdm2 interaction, indicating that the Ser395 site is sufficient
and necessary. Mdm2 can also be phosphorylated on Y394 by
the ATM substrate c-Abl (Goldberg et al., 2002). However, the
binding of the p53 mRNA to Mdm2S394A in response to geno-
toxic stress was similar to that of Mdm2wt, indicating that this
site plays a minor role in controlling RNA binding and at the
same time indicates the regulatory specificity of the Ser395
residue (Figure 3A; Figure S3A, left panel). To further test whether
the binding of the p53mRNA to Mdm2 is controlled by ATM, we
used the AT5-BIVA cells. qRNA-coIP using the 4B2 monoclonal
Antibody (mAb), which is indifferent to Mdm2’s Ser 395 phos-
phorylation status, revealed almost no p53 mRNA bound to
Mdm2 in these cells. The introduction of ATM restored p53Cancer Cell 21, 25–35, January 17, 2012 ª2012 Elsevier Inc. 27
Figure 2. Phosphorylation of Mdm2 at
Ser395 Induces p53-Dependent Apoptosis
Independently of the p53–Mdm2 Protein-
Protein Interaction
(A) The effect of the Mdm2p76 isoform on p53-
dependent apoptosis was evaluated in H1299
cells in the presence or absence of genotoxic
stress (doxo 0.1 mM for 16 hr). Doxo-treated and
nontransfected cells were given the arbitrary
value zero.
(B) The effect on p53-dependent apoptosis by
Mdm2S395A in the presence of doxo in indicated
cells. Cells were transfected with p53wt and
with Mdm2wt or Mdm2S395A. The ATM/ cells
(AT5-BIVA) were also transfected with ATM.
Apoptosis in the presence of Mdm2wt, p53wt
and doxorubicin was given the arbitrary value
100. Mdm2/;p53/ double knock-out MEF
cells (DKO).
(C) p53-dependent apoptosis in H1299 cells ex-
pressing indicated p53 and Mdm2 constructs in
the absence, or presence, of doxo. Data are
means ± s.d. of at least three independent
experiments (*p < 0.05, **p < 0.01, ***p < 0.001).
P values are as compared with doxo and noMdm2
(A), Mdm2wt (B), and Mdm2wt and p53wt (C). The
data using H1299 cells (A and C) are normalized
to the levels of apoptosis in mock-transfected
cells (0%).
See also Figure S2.
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Mdm2 Activates p53 following Genotoxic StressmRNA binding to Mdm2, and the affinity of this interaction
increased by approximately four-fold after doxorubicin treat-
ment. Importantly, when we instead used the 2A10 mAb, which
does not recognize the phosphorylated Ser 395 epitope (Maya
et al., 2001), we detected little p53 mRNA in the qRNA-coIP
even in the presence of ATM, indicating that nonphosphorylated
Mdm2 has weak affinity to the p53 mRNA (Figure 3B; Fig-
ure S3B). In order to investigate whether ATM-dependent phos-
phorylation at Mdm2Ser395 regulates Mdm2’s binding to the
p53 mRNA, we performed in vitro binding experiments in which
ATM immunoprecipitated from cell lysate was added to re-
combinant Mdm2 purified from Sf9 insect cells and in vitro tran-
scribed p53mRNA (Figure S3C). Treatment of cells with doxoru-
bicin prior to cell lysis resulted in an approximately four-fold
increase in the amount of p53 mRNA bound to Mdm2. This
increase was suppressed bymore than 50% if ATMi or wortman-
nin were added to the reaction mixture. We also tested the low-
affinity p53L22LmRNA under these in vitro conditions and found
that its interaction with Mdm2 in response to doxorubicin treat-
ment was less than half of that of the wild-type message (Fig-
ure 3C). Furthermore, the ATM-dependent increase in the
binding of p53 mRNA to Mdm2 in vitro could be detected using
the 4B2 but not the 2A10 mAb (Figure 3D).
Mdm2 is mainly detected in the nucleus in response to stress,
but Mdm2-dependent synthesis and degradation of p53 takes
place in the cytoplasm, so we wanted to know where the
p53 mRNA-Mdm2 interaction takes place. To address this
question, we deleted the nuclear localization signal in Mdm228 Cancer Cell 21, 25–35, January 17, 2012 ª2012 Elsevier Inc.(Mdm2DNLS). Interestingly, this protein is restricted to the
cytoplasmic compartment and binds the p53 mRNA in vitro
(O’Keefe et al., 2003 and data not shown) but it only interacts
with a fraction of the p53 mRNA, as compared with the
Mdm2wt, indicating that the p53 mRNA-Mdm2 interaction
mainly takes place in the nucleus (Figure 3E; Figure S3A, right
panel).
We further characterized the p53 mRNA-Mdm2 interaction
using a biotinylated oligonucleotide corresponding to the
Mdm2-binding sequence of p53 mRNA (MBD-ES) and purified
recombinant Mdm2 proteins expressed in bacteria (Figure S3D).
The Mdm2wt showed low affinity for the p53MBD-ES, whereas
the phospho-mimetic Mdm2S395D displayed a higher esti-
mated affinity (Kdiss 160 nM) (Figures 3F and 3G). An Mdm2
construct that contains the C-terminal residues 322–491,
Mdm2(322-491), showed a similar behavior as the full-length
Mdm2 protein in that the 395D mutation enhances the RNA-
binding capacity. However, a construct including the RING
domain, but not Ser395, Mdm2(396-491), showed a similar
affinity (Kdiss 400 nM) for the RNA as MdmS2395D, indicating
that the RING domain alone is sufficient to bind the p53 mRNA
(Figure 3H). These results suggest that the RNA-binding capacity
of Mdm2 takes place in the nuclear compartment and is located
to the RING domain of Mdm2 and that the 395 residue is not part
of the direct contact with the p53mRNA. This also indicates that
phosphorylation of Ser395 by ATM promotes Mdm2’s RNA-
binding capacity via allosteric changes within the C terminus of
Mdm2.
Figure 3. The Binding of the p53 mRNA to Mdm2 Is Dependent on ATM Activity
(A) The binding of indicatedMdm2 constructs to the p53mRNA in H1299 cells as estimated using qRNA-coIP. Cells (A–E) were treated with doxo (1 mM for 3 hr) or
DMSO. ATM inhibitor (ATMi 10 mM) or the PI3K inhibitor wortmannin (wort. 5 mM) was added for 20 hr before RNA binding was determined.
(B) The binding of p53mRNA to Mdm2 in the ATM null AT5-BIVA cells with, or without, exogenous ATM using qRNA-coIP. The anti-Mdm2 monoclonal antibody
(mAb) 4B2 is indifferent to phosphorylation, whereas 2A10 does not recognize the phosphorylated Ser395 Mdm2 epitope.
(C) ATM immunoprecipitated from H1299 cells treated, or not, with doxo was added to recombinant purified Mdm2 from Sf9 insect cells and in vitro-synthesized
p53wt or p53L22L mRNAs in the presence or absence of ATMi (10 mM) or wortmannin (5 mM), and the amount of p53 mRNA bound to Mdm2 was estimated
following qRNA-coIP.
(D) ATM-dependent changes in the in vitro binding of p53 mRNA to Mdm2 as in (C) using 4B2 and 2A10 mAbs.
(E) The binding of Mdm2 wild-type (WT) to the p53 mRNA in H1299 cells or to an Mdm2 that lacks the nuclear localization signal (DNLS) as estimated using
qRNA-coIP.
(F) Cartoon illustrating different domains of Mdm2.
(G) In vitro purified recombinant Mdm2wt or Mdm2S395D expressed in bacteria were tested for their binding to in vitro synthesized p53mRNA using RNA-ELISA.
(H) In vitro purified truncated recombinant Mdm2 proteins expressed in bacteria were tested for their binding to in vitro synthesized p53mRNA using RNA-ELISA.
Data aremeans ± s.d. of three independent experiments (*p < 0.05, **p < 0.01, ***p < 0.001). P values are as comparedwith Doxo andMdm2wt (A, E), no Doxo and
ATM (B), Doxo alone (C) and mAb 4B2 (D).
See also Figure S3.
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Mdm2 Activates p53 following Genotoxic StressThe p53 mRNA Is Required for Mdm2 SUMO-
Conjugation and Nuclear Trafficking
After DNA damage, Mdm2 localizes to nucleoli and this plays an
important role in p53’s capacity to respond to DNA damage
(Lohrum et al., 2000; Weber et al., 1999). Mdm2 also interacts
with PML that is linked to RNA transport, and we tested whether
the p53 mRNA plays a role in Mdm2 nuclear translocation (Ber-
nardi et al., 2004; Cohen et al., 2001; Ideue et al., 2004; Kurki
et al., 2003). Treatment of p53wt-expressing cells with doxoru-bicin resulted in the localization of Mdm2 to nucleoli in conjunc-
tion with PML nuclear bodies, as reported previously (Figure 4A,
top two rows; Figure S4) (Bernardi et al., 2004; Kurki et al., 2003).
Interestingly, the localization of Mdm2 to nucleoli after genotoxic
stress was abrogated by suppressing the interaction between
Mdm2 and the p53 mRNA using mutants Mdm2S395A or
p53L22L (Figure 4A, lower panel). The expression of a silent
p53 construct (Sp53 mRNA) lacking initiation codons and that
expresses no p53 protein (Candeias et al., 2008) revealed thatCancer Cell 21, 25–35, January 17, 2012 ª2012 Elsevier Inc. 29
Figure 4. The p53 mRNA Regulates Mdm2 SUMOylation and Nuclear Trafficking
H1299 cells were transfected with indicated constructs and Mdm2, PML, or B23/NPM was detected by indirect immunofluorescence microscopy staining. Cell
nuclei were visualized with DAPI (blue). Fields were merged to assess protein colocalization.
(A) Cells expressing indicated p53 and Mdm2 constructs and treated with DMSO (upper panels) or doxo (middle panels) and stained for PML (green) and Mdm2
(red). The lower panels show staining of Mdm2 in cells overexpressing indicated Mdm2 and p53 constructs after treatment with doxo.
(B) Mdm2 staining in cells expressing indicated constructs and treated with doxo or DMSO.
(C) DuoLink using anti-SUMO1/2 and anti-Mdm2 specific mAbs. Fusion of SUMO1 to Mdm2 (Mdm2-SUMO1) serves as a positive control (upper left). Mdm2
conjugated to endogenous SUMO1/2 is shown in the other slides. Treatment with etoposide leads to an accumulation of SUMOylated Mdm2wt products in
nucleoli (white arrow, top right).
(D) Double staining for Mdm2 using 4B2 mAb and anti-B23/NPM polyclonal sera. Data represent three similar independent experiments. Scale bars correspond
to 10 mm.
See also Figure S4.
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Mdm2 Activates p53 following Genotoxic Stressthe p53mRNA, but not the p53 protein, is required for the nucle-
olar localization of Mdm2 following genotoxic stress. We also
observed that the phosphomimetic S395D mutation resulted in
an Mdm2 that, in the presence of the Sp53 mRNA, localized to
the nucleoli in the absence of genotoxic stress (Figure 4B).
SUMO modifications can play a role in nucleolar and PML-
related nuclear trafficking, and we used the DuoLink method,
which gives a single signal if two different antibody epitopes
are localized within 40 nm of each other, to detect and visualize
SUMO-conjugated Mdm2 under normal or genotoxic stress
conditions. By using antibodies toward Mdm2 and SUMO, we30 Cancer Cell 21, 25–35, January 17, 2012 ª2012 Elsevier Inc.could confirmpositive signals throughout the cells using a control
Mdm2-SUMO1 fusion construct. Mdm2 wild-type protein was
weakly SUMOylated throughout nontreated cells in the presence
of p53. Treating cells with etoposide (doxorubicin interferes with
the DuoLink signal) in the presence of Sp53mRNA resulted in an
increase in SUMOylated Mdm2 throughout the nucleus and an
accumulation in nucleoli. This was prevented if the cells were
treated with the ATMi. Introducing the S395D mutation resulted
in an increase in the number of Mdm2-SUMO interactions in
nontreated cells. Importantly, when the Sp53 mRNA was coex-
pressed with the Mdm2S395D, the SUMOylation of Mdm2 in
Figure 5. DNA Damage Stimulates ATM-
Dependent p53 mRNA Translation and p53
Polyubiquitination and Degradation
(A) Autoradiograph of a metabolic pulse label in
H1299 cells expressing p53 and Mdm2wt or
Mdm2DNLS in the presence of proteasome
inhibitor (MG132 20 mM for 2 hr) followed by
p53 IP.
(B) Metabolic pulse-label reveals synthesis of p53
in H1299 cells transfected with indicated con-
structs and treated, or not, with doxo (0.1 mM for
10 hr) and the specific ATM inhibitor (ATMi; 10 mM
for 20 hr).
(C) Cells expressing indicated p53 and Mdm2
constructs were treated, or not, with doxo, and
the p53 ubiquitination patterns were visualized
after separation on a 7% SDS gel and blotted
against p53 CM-1 polyclonal sera. Mono- and
polyubiquitinated p53 forms are indicated.
(D) Cells were transfected with ubiquitin-His tag
cDNA and indicated constructs in the presence or
absence of genotoxic stress. Cells were treated
with the proteasome inhibitor epoxomicin (5 mM
4 hr). Upper panel shows lower-molecular-weight
ubiquitin-His conjugated p53 proteins after en-
richment on Ni-Agarose beads, separated on SDS
gels and blotted against p53 (CM-1 pAb). The
graph below shows the relative values of three
independent experiments as determined by ECL
reader. Bottom panels shows corresponding p53
steady state levels (no proteasome inhibitors) and
actin loading control.
(E) The graph shows the relative changes in p53
stability in the presence of indicated Mdm2 and
p53 constructs after doxo treatment (0.1 mM for 10 hr) followed by cycloheximide for 1 hr prior to lysis. p53 levels in the absence of exogenous Mdm2 was set to
100%. Data are representative of three similar independent experiments and are expressed as means ± s.d. (*p < 0.05, **p < 0.01, ***p < 0.001). P values are as
compared with doxo alone (B) and Mdm2wt and p53wt (E) and p53wt mRNA (D). See also Figure S5.
Cancer Cell
Mdm2 Activates p53 following Genotoxic Stressnontreated cells was enhanced over 10-fold and restricted to the
nucleoli (Figure 4C). We also tested whether conjugation of
SUMO1 to Mdm2 plays a direct role in the accumulation of
Mdm2 in the nucleolus. Fusion of SUMO1 to Mdm2S395A
(Mdm2S395A-SUMO1) resulted in a localization of the fusion
protein to the nucleoli under stress conditions and without the
presence of p53 mRNA (Figure 4D). These results show that
the p53 mRNA plays an important role in directing Mdm2
SUMO modification and its nuclear trafficking.
ATM and the p53mRNA-Mdm2 Interaction Are Required
to Induce p53 Expression following Genotoxic Stress
The binding of the p53 mRNA to Mdm2 has been shown to
promote p53 synthesis. Metabolic pulse-label experiments in
the presence of proteasome inhibitors showed that the Mdm2
protein, which lacks the nuclear localization sequence (DNLS),
does not support p53 synthesis (Figure 5A). This indicates that,
even though synthesis of p53 takes place in the cytoplasm, the
p53 mRNA-Mdm2 interaction needs first to take place in the
nucleus (Figure 3E). In line with the observation that ATM activity
promotes the interaction between the p53mRNA andMdm2, we
found that Mdm2 induces more than three-fold increase in the
rate of p53 synthesis after cells were exposed to doxorubicin,
as compared to nontreated cells. This increase was suppressed
by more than 60% if the cells were also treated with the ATMi.
The induction of p53 synthesis by endogenous Mdm2 afterdoxorubicin treatment is approximately 50% (Figure 5B;
Figure S5).
The degradation of p53 by Mdm2 involves p53 poly-
ubiquitination, and managing Mdm2’s E3 ligase activity toward
p53 following DNA damage is important for p53 activation (Li
et al., 2003; Thrower et al., 2000). The binding of the p53
mRNA to the RING domain of Mdm2 can control Mdm2 E3 ligase
activity (Candeias et al., 2008; Linares and Scheffner, 2003), we
therefore investigated how Mdm2Ser395 phosphorylation
and p53mRNA binding affects p53 ubiquitination. Treating cells
with proteasome inhibitors prior to lysis revealed that the Mdm2-
dependent polyubiquitination of p53 is compromised in cells
treated with doxorubicin or when the 395D mutation is intro-
duced in Mdm2 (Figure 5C). Monoubiquitination of p53, which
can take place on several lysine residues, was relatively unaf-
fected. We also enriched ubiquitinated p53 by expressing a
His-ubiquitin construct followed by Ni+-agarose purification.
Using either method, we could not detect Mdm2-dependent pol-
yubiquitinated p53 when p53wt protein was expressed from the
L22LmRNA, but we could detect Mdm2-dependent His-ubiqui-
tinated p53 of less than 90 kD (Figure 5D, upper and middle
panel). Importantly, in the presence of genotoxic stress, or by
introducing the 395D mutation in Mdm2, we observed a signifi-
cant reduction in the amount of His-ubiquitinated p53 products
of lower molecular weight when the p53wt protein was ex-
pressed from the L22L mRNA, as compared to the p53wtCancer Cell 21, 25–35, January 17, 2012 ª2012 Elsevier Inc. 31
Figure 6. A Model for p53 Activation via ATM-Mdm2 in Response to
Genotoxic Stress
Under normal conditions, Mdm2 translocates the p53 protein out of the
nucleus for degradation via the ubiquitin-dependent pathway. Under condi-
tions of genotoxic stress, ATMphosphorylatesMdm2 at Ser395. This results in
allosteric changes in the C terminus of Mdm2 and opens up the Mdm2 RING
domain for p53 mRNA binding, which, in turn, promotes Mdm2 SUMO-
conjugation and its accumulation in the nucleolus. The p53 mRNA-Mdm2
interaction stimulates p53mRNA translation and suppresses Mdm2 E3 ligase
activity toward p53 and is required for p53 activation following DNA damage.
Suppressing the p53 mRNA interaction, via either a single silent point muta-
tion in the p53 mRNA (p53L22L) or an amino acid substitution in Mdm2
(Mdm2S395A), leads to a decrease in p53 levels upon genotoxic stress and
a failure to activate the p53 pathway. These results illustrate the importance of
the p53mRNA in the genotoxic stress pathway and how it controls the activity
of Mdm2 toward the p53 protein and offers an explanation to why Mdm2 is
upregulated by p53 in response to DNA damage.
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Mdm2 Activates p53 following Genotoxic StressmRNA, for which the ubiquitination pattern was relatively un-
changed under these conditions. At the same time, we observed
a sharp decrease in the steady-state levels of p53wt protein ex-
pressed from the p53L22L mRNA in the presence of either
Mdm2S395D or Mdm2wt plus doxorubicin. The levels of p53wt
protein expressed from the p53wtmRNA increased under these
conditions (Figure 5D, lower panels). This shows that p53wt
protein expressed from a non-Mdm2 binding mRNA is hyper-
unstable in the presence of Mdm2 during genotoxic stress.
The importance of the p53 mRNA-Mdm2 interaction in pre-
venting p53 degradation following genotoxic stress was
further underlined by introducing the Mdm2G446S and the
Mdm2395A mutants, which both have a low affinity for the
p53wt mRNA. Following doxorubicin and cycloheximide treat-
ment (1 hr), we observed an approximately five-fold higher p53
turnover rate in cells expressing a dysfunctional combination of
the p53 mRNA-Mdm2 interaction (Figure 5E). These results
support the notion that the increase in the p53 mRNA-Mdm2
binding following genotoxic stress leads to both an increase in
Mdm2-dependent p53 synthesis and a decrease in Mdm2-
dependent degradation p53.
DISCUSSION
The results presented here describe the molecular mechanisms
underlying ATM-dependent regulation of Mdm2 nuclear traf-
ficking and p53 activation following genotoxic stress and offer
an additional view on p53-dependent induction ofMdm2 expres-
sion. Our results support a model in which the induction of the
p53 mRNA-Mdm2 interaction takes place in the nuclear
compartment in response to genotoxic stress via ATM-depen-
dent phosphorylation of Mdm2 at Ser395. This event leads to
a change of conformation in the Mdm2 RING domain that
exposes the binding site for the p53 mRNA. This, in turn,
promotes Mdm2 SUMOylation and brings Mdm2 to the nucle-
olus and switches Mdm2 into a positive regulator of p53 by
increasing p53 synthesis and, at the same time, suppresses
Mdm2-dependent degradation of p53. When the DNA damage
signaling cascade is turned off, ATM activity ceases and
Mdm2 phosphorylation is reversed by Wip1 so that Mdm2 no
longer binds the p53mRNA and switches to become a negative
regulator of p53 activity by promoting p53 polyubiquitination and
degradation (Figure 6). Disruption of the p53mRNA-Mdm2 inter-
action leads to a rapid decrease in p53 levels and to a failure in
p53 activation in response to genotoxic stress.
Our results show that Mdm2p76 is a positive regulator of p53
activity in response to DNA damage, despite lacking the p53
interactive N-terminal domain, demonstrating that disrupting
the p53-Mdm2 protein-protein interaction by ATM-dependent
modifications of the p53 N terminus, or on Mdm2, are not
required to induce p53 activity following ATM activation. Pre-
venting the p53-Mdm2 protein-protein interaction could help to
explain how ATM neutralizes the negative effect of Mdm2 but it
cannot explain how Mdm2 actually stimulates p53 activity
following genotoxic stress. Our data suggest that, in addition
to preventing Mdm2-dependent degradation of p53, the p53
mRNA-Mdm2 interaction also stimulates p53 synthesis and
together these two effects can account for the positive outcome
of Mdm2 on p53 expression and activity in response to DNA32 Cancer Cell 21, 25–35, January 17, 2012 ª2012 Elsevier Inc.damage. The activation of p53 via DNA damaged-inducedmodi-
fications on the p53 N terminus have been suggested, but we
observed only a relative small additive effect on p53-dependent
apoptosis after doxorubicin treatment in the presence of
Mdm2S395D, as compared to the differences observed using
the Mdm2wt. No significant difference with or without doxoru-
bicin was found when we knock out Mdm2 in cells expressing
endogenous p53wt. This indicates that under these conditions
ATM-mediated phosphorylation of p53 plays a less important
role in activating p53.
It is interesting to notice that expression of a p53wt protein
from the L22L mRNA with low affinity for Mdm2, or expression
of the wild-type p53 mRNA in the presence of the non-RNA-
binding Mdm2S395A mutant, results in an increase in p53
turnover rate following genotoxic stress, as compared to the
stabilization observed using p53wt mRNA and Mdm2wt. More
recently, it was suggested that phosphorylation of the C terminus
of Mdm2 induces its monomerization and prevents p53 poly-
ubiquitination (Cheng et al., 2009). Our results do not go against
this model, but they show that the phosphorylation of Ser395
induces the p53 mRNA-Mdm2, interaction which is necessary
to inhibit p53 polyubiquitination. The molecular mechanism of
the p53 mRNA-mediated control of Mdm2 E3 ligase activity is
not clear and might include a direct interference with the ligase
activity, disruption of Mdm2 dimerization, or the interaction
with proteins interacting with the C terminus of Mdm2, such as
the ubiquitin protease HAUSP (Cummins et al., 2004; Li et al.,
2004, 2002).
The localization of Mdm2 to the nucleoli is an important step
in p53 activation, and the observation that Mdm2 requires
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Mdm2 Activates p53 following Genotoxic StressphosphorylationofSer395and the interactionwith thep53mRNA
to locate to nucleolar structures following genotoxic stress
further adds to the important role of the p53mRNA in controlling
Mdm2 functions. The RNA-binding capacity of other nucleolar
factors such as nucleolin and NRF have been suggested to play
a role in their respective nucleolar accumulation (Emmott and
Hiscox, 2009; Niedick et al., 2004), suggesting that RNA-directed
nucleolar trafficking is a more widespread concept. The require-
ment for Ser395phosphorylation andp53mRNA-binding in order
to translocate Mdm2 to the nucleolus becomes redundant if
SUMO1 is conjugated to Mdm2, indicating that these two events
precede SUMO-modification and translocation. In support of the
idea that phosphorylation of Ser395 is the first step in this chain
of events, we observed that the Mdm2S395D mutant does
not localize to the nucleolus following genotoxic stress in the
absence of the p53 mRNA. Because phosphorylation of Ser395
is required for Mdm2’s interaction with the p53 mRNA in vitro
and the Mdm2S395D binds p53 mRNA with higher affinity in
the cell, it is unlikely that p53 mRNA binding to Mdm2 would be
an indirect effect of SUMO-conjugation. The role of Mdm2-inter-
acting factors inp53mRNA-mediated localization ofMdm2 to the
nucleoli will be addressed separately (Poyurovsky et al., 2003;
Tao and Levine, 1999).
Mdm2 binds to a region of the p53mRNA that has been shown
to contain an IRES sequence (Candeias et al., 2008; Gu et al.,
2009; Ray et al., 2006). Mdm2 requires nuclear localization to
bind the p53 mRNA and promote p53 mRNA translation during
genotoxic stress, indicating that the accumulation of Mdm2 in
the nucleolus serves an important function in assembling the
p53 mRNA-Mdm2 translation complex. Because eukaryotic
IRES trans-activating factors (ITAFs) are known to shuttle
between nucleus and cytoplasm, and some to require expres-
sion in the nuclear compartment in order to promote translation
in response to cellular stresses, it is possible that the trans-local-
ization of Mdm2 within the nucleus to support synthesis of p53
during genotoxic stress reflects a more general aspects of
stress-dependent mRNA translation.
Finally, an interesting aspect of these results is that they offer
an explanation to the paradox of the rapid induction of Mdm2 by
p53 in response to genotoxic stress (Mendrysa and Perry, 2000).
As long as the ATM pathway is active and the interaction with the
p53 mRNA is present, Mdm2 serves as a positive regulator of
p53 activity but as soon as this activity ceases, Mdm2 returns
to be a negative regulator to ensure the suppression of p53
activity under normal conditions.
EXPERIMENTAL PROCEDURES
Cell Lines, Protein Labeling, and Expression
All cell-based assays were performed in p53/ H1299, p53WT MLS-1765,
ATM/ AT5-BIVA, or p53/;Mdm2/ Double-KO MEF (DKO) cells. For all
experiments, transfection efficiency and mRNA levels were verified using
reverse transcription quantitative PCR (RT-qPCR). 35S-methionine labeling
was performed by culturing cells in methionine-free medium including 2%
dialyzed FCS for 1 hr and 20 mM of the proteasome inhibitor MG132 (Merck
Biosciences, UK). Cells were transfected using Genejuice (Novagen). Easytag
Express Protein Labeling Mix (90 mCi; 35S) (PerkinElmer, Boston, USA) was
added for 20 min, and p53 proteins were immunoprecipitated using CM-1
antibody and separated by SDS-PAGE. In vitro transcribed capped mRNAs
(Ambion, Austin, TX, USA) were prepared according to the manufacturer’s
protocol. Quantification of radioactively labeled products was determinedusing phosphoimager (Amersham) and Storm hardware together with
Bio-1D software (Vilber-Lourmat). Cycloheximide (CHX, Calbiochem), Doxoru-
bicin (Sigma), Etoposide (Sigma), ATM Kinase Inhibitor (ATMi, Calbiochem),
and wortmannin (Calbiochem) or an equal volume of dimethylsuphoxide
(DMSO) were used at the concentrations of 10 mg/ml, 0.1–1 mM (depending
on the sensitivity of the cell type), 20 mM, 10 mM, and 5 mM, respectively, for
the time durations indicated in the figure legends. CM-1, 4B2, 4B11, 2A10,
and 1.2 antibodies were all kind gifts from Borek Vojtesek. siRNAs against
Mdm2 and ATM were from QIAGEN and were applied according to the manu-
facturer’s recommendations. Cells were transfected with 0.3 mg cDNA per
6-cm dish unless otherwise stated.
His-Ubiquitin Conjugation
Cells (1 3 106) were seeded on 10-cm tissue culture plates and transfected
with 0.8 mg of plasmids encoding Mdm2, 6His-Ubiquitin, and p53. Twenty-
eight hours after transfection, cells were treated with 0.1 mM of doxorubicin
for 16 hr. Proteasome inhibitor MG-132 (25 mM) was added 4 hr before cells
were washed twice with PBS and scraped in 1 ml of lysis buffer (6 M guanidi-
nium-HCl, 0.1 M Na2HPO4/NaH2PO4, 0.01 M Tris-HCl [pH 8], 0.005 M imida-
zol, and 0.01 M b-mercaptoethanol). The cells were sonicated twice for 10
sec. After sonication, 4 ml of lysis buffer was added with 75 ml of Ni2+-NTA-
agarose beads (Clontech) and was incubated for 4 hr at RT with gently agita-
tion. The beads were washed once at RT in lysis buffers, once in wash buffer
(8 M urea, 0.1 M Na2HPO4/NaH2PO4, 0.01 M Tris-HCl [pH 6.8], 0.005 M imida-
zol, and 0.01 M b-mercaptoethanol), and twice in wash buffer plus 0.1% Triton
X-100. Products were eluted by incubating beads in 75 ml of 0.2 M imidazol,
0.15 M Tris-HCl (pH 6.8), 30% glycerol, 0.72 M b-mercaptoethanol, and 5%
SDS for 20 min at RT with gentle agitation. Twenty-five microliters of 43 of
Laemmeli buffer were added before being analyzed by western blot.
Flow Cytometry
The measurement of the percentage of apoptotic cells in a population was
effectuated as described elsewhere (Vermes et al., 1995). Briefly, transfected
cells were stained with annexin V-FITC and 7-Aminoactinomycin D (7-AAD)
(Sigma, Missouri, USA) and were analyzed by flow cytometry with an LSR
flow cytometer and CellQuest software (Becton Dickinson, San Jose, CA,
USA). The test discriminates intact cells (FITC/7-AAD), apoptotic cells
(FITC+/7-AAD) and necrotic cells (FITC+/7-AAD+).
Quantitative RNA Coimmunoprecipitation
Quantitative RNA Coimmunoprecipitation (qRNAco-IP) assays were based on
a previous protocol (Candeias et al., 2008; Tenenbaum et al., 2002). Briefly,
transfected H1299 cells were lysed with a buffer containing RNase OUT
(100 U/ml, Invitrogen) and centrifuged, and supernatants were precleared
with mouse IgG followed by incubation with one of the monoclonal anti-
Mdm2 antibodies: SMP14 (directed against amino-acids [aa] 154–167 of
Mdm2), 4B2 (recognizes the N terminus of Mdm2) or 2A10 (directed against
aa 393–395, cannot bind to Mdm2 that is phosphorylated at Ser395). The
complexes were pulled-down using protein G–Sepharose beads (Amersham)
treated with proteinase K (Sigma), and RNA was extracted and purified using
TRIzol protocol (Invitrogen). RT-qPCR was performed using primers against
p53 and control genes TATA Box-binding protein and b-actin. To ensure valid
quantification of RNA binding to Mdm2, standard curves were used to attest
for transfection, RT-PCR, and qPCR protocols’ efficiency. RT-qPCRs on total
RNA were realized, and qRNAco-IP values calculated according to the
following formula: (qPCRvalue p53mRNA IP / qPCRvalue p53mRNA total) /
(qPCRvalue controlmRNA IP / qPCRvalue controlmRNA total). A western
blot anti-Mdm2 was done in parallel, and coimmunoprecipitation data were
also normalized against total Mdm2 protein when needed.
In Vitro Quantitative RNA Coimmunoprecipitation
All binding reactions were performed for 15 min at 37C in a binding buffer con-
taining50mMTris (pH7.5),150mMNaCl, 0.02mg/mlyeast tRNA,and0.2mg/ml
BSA. ATM protein was included after being immunoprecipitated from H1299
cells using 10 mg of phosphorylation-specific antibody anti-phospho-ATM
(Ser1981) (Millipore). One hundred twenty nanograms of hMdm2protein purified
from insect cells and a fixed amount (8.103 pmol) of WT or L22L p53 mRNA
were used. ATM Kinase Inhibitor (10 mM; ATMi, Calbiochem) or 5 mM ofCancer Cell 21, 25–35, January 17, 2012 ª2012 Elsevier Inc. 33
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incubation, RNA-protein complexes were pulled-down using monoclonal anti-
Mdm2 antibodies 4B2 or 2A10 and protein G beads (Amersham). The unbound
fraction was recovered for later analysis, and the bound RNA was treated with
proteinase K (Sigma). The bound and free RNA fractions were then extracted
and purified using TRIzol protocol (Invitrogen). RT-qPCR was performed on
these fractions using primers against p53. The binding results were expressed
as a ratio between the bound and the total (bound+free) RNA.
Protein-RNA ELISA Assay
Ninety-six-well plates were coated with streptavidin (100 mg/ml in 0.1 M
NaHCO3; 50 ml/well) overnight at 4C. After incubation, plates were washed
six times with 200 ml PBS-T and blocked with 50 ml of 3% BSA and 0.1 mg/ml
of streptavidin in PBS overnight at 4C. The plates were washed four times
with 0.1%PBS-Tween. Amixof biotinylatedRNA (5pmol) anddifferent amounts
ofproteinpreviously incubated inabindingbuffercontaining50mMTris (pH7.5),
150 mM NaCl, 0.02 mg/ml yeast tRNA, and 0.2 mg/ml BSA for 30 min at 37C
were added to the plates (50 ml/well) and incubated 1 hr at RT. The plates
were washed six times with 200ml/well PBS-T, and the 6His mAB/HRP con-
jugate (Clontech) in PBS 1:1000 (50 ml/well) was added and incubated for 1 hr
at RT. Plates were washed six times with 200 ml/well PBS-T, and 50 ml/well of
a mix of ECL was added and luminescence was measured. Biotinylated MS2
RNA oligonucleotide was used as a negative control to RNA binding specificity.
Immunofluorescence and Fluorescence Microscopy
H1299 cells were grown on coverslips and treated as indicated. Cells were
fixed in 4% paraformaldehyde for 10 min before permeabilization in PBS con-
taining 0.1% Triton X-100 for 2 min. The antibodies used for immunofluores-
cence microscopy were anti-PML (rabbit; Abcam), anti-Mdm2 (mouse; 4B2;
gift from B. Vojtesek), anti-nucleolin (mouse; Abcam), and anti-SUMO1 anti-
SUMO2 (sheep; gift from R.T. Hay). Double staining was performed as
indicated. For detection, cells were incubated with Alexa-488-conjugated
(Invitrogen) or Cy5-conjugated (Molecular probes) anti-rabbit antibodies and
Alexa Fluor-568-conjugated (Invitrogen) or Alexa Fluor-633-conjugated (Invi-
trogen) anti-mouse antibodies.
Duolink
Duolink (Olink) was performed according to the manufacturer’s instructions.
Briefly, H1299 cells were grown on coverslips and then fixed in 4%paraformal-
dehyde for 10 min before permeabilization in PBS containing 0.1% Triton
X-100 for 2 min. Cells were then blocked in 3% BSA/BPS and primary anti-
bodies were incubated (anti-Mdm2, anti-SUMO1, and anti-SUMO2). After
washing the cells, PLA probes were added, followed by hybridization, ligation,
and amplification for 90 min at 37C. DNA (blue) and Mdm2-SUMO interac-
tions (red) were visualized after incubation with the Detection solution. Slides
were analyzed by fluorescence microscopy.
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